Limits...
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.

Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, von Dadelszen P, Community Level Interventions for Pre-eclampsia (CLIP) Working Gro - BJOG (2014)

Bottom Line: There were no differences in adverse maternal or fetal outcomes.Target BP was achieved ~ 50% of the time with oral labetalol (100 mg) or methyldopa (250 mg) (47% labetelol versus 56% methyldopa; RR 0.85 95% CI 0.54-1.33).Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada.

Show MeSH

Related in: MedlinePlus

Literature search results.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4282072&req=5

fig01: Literature search results.

Mentions: Of 465 papers identified, 16 published from 1982 to 2011 met eligibility criteria: 15 in pregnancy12–29 (914 women) (one of which was a three-armed trial)26 and one a postpartum trial (38 women)24 (Figure1). Two abstracts were later published as full studies.28,29 The reasons for exclusion were: no randomisation,30,31 enrolment of women with nonsevere hypertension,32 failure to identify one antihypertensive treatment arm as administered orally or parenterally,33 and inability to obtain abstracts for review (despite contacting our local libraries and the Cochrane library).34,35


Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.

Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, von Dadelszen P, Community Level Interventions for Pre-eclampsia (CLIP) Working Gro - BJOG (2014)

Literature search results.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4282072&req=5

fig01: Literature search results.
Mentions: Of 465 papers identified, 16 published from 1982 to 2011 met eligibility criteria: 15 in pregnancy12–29 (914 women) (one of which was a three-armed trial)26 and one a postpartum trial (38 women)24 (Figure1). Two abstracts were later published as full studies.28,29 The reasons for exclusion were: no randomisation,30,31 enrolment of women with nonsevere hypertension,32 failure to identify one antihypertensive treatment arm as administered orally or parenterally,33 and inability to obtain abstracts for review (despite contacting our local libraries and the Cochrane library).34,35

Bottom Line: There were no differences in adverse maternal or fetal outcomes.Target BP was achieved ~ 50% of the time with oral labetalol (100 mg) or methyldopa (250 mg) (47% labetelol versus 56% methyldopa; RR 0.85 95% CI 0.54-1.33).Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada.

Show MeSH
Related in: MedlinePlus